Table 1 Baseline characteristics of patients undergoing P-EOIT (N = 69 per protocol)
Sex: male, n (%) | 38 (55.1) |
Age (months) at entry into OIT, median (IQR) | 13 (8) |
     ≤ 12 months, n (%) | 32 (46.4) |
    13–24 months, n (%) | 34 (49.3) |
    25–36 months, n (%) | 3 (4.3) |
Other atopic conditions, n (%) | 56 (81.1) |
    Eczema | 54 (78.3) |
    Asthma | 6 (8.6) |
    Allergic rhinitis | 1 (1.4) |
Sibling with peanut allergy, n (%) | 4 (5.8) |
Other food allergies, n (%) | 37 (53.6) |
    Egg | 31 (44.9) |
    Milk | 10 (14.5) |
    Sesame | 7 (10.1) |
    Tree nut | 5 (7.2) |
Initial allergic reaction to peanut, n (%) | 65 (94.2) |
Age (months) at initial reaction, median (IQR) | 8 (5) |
No. of months between peanut reaction and first OIT dose, median (IQR) | 3 (3) |
Baseline peanut SPT in mm, median (IQR) | 8 (4) |
    No data, n (%) | 6 (8.7) |
    Negative, n (%) | 4 (5.8) |
Baseline peanut specific IgE level, kUA/L, median (IQR) | 1.78 (3.98) |
    No data, n (%) | 1 (1.4) |
    <0.1 kUA/L, n (%) | 2 (2.9) |
Referral source, n (%) | |
    Family physician | 42 (60.9) |
    Pediatrician | 11 (15.9) |
    Emergency department | 8 (11.6) |
    Allergist | 4 (5.8) |
    Nurse practitioner | 4 (5.8) |
Peanut protein type used in buildup, n (%) | |
    Bamba-only | 5 (7.2) |
    Peanut flour-only | 7 (10.1) |
    Hybrid | 57 (82.6) |